Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with non-small cell lung cancer (NSCLC) that has been confirmed by a tissue sample, can be surgically removed, and is at a higher risk of coming back — based on specific features such as: the tumour being larger than 4cm; cancer that has spread to nearby lymph nodes; cancer that has grown into surrounding structures in the chest; or a separate tumour nodule found in the same lobe as the main tumour
- People with locally advanced or widespread NSCLC of the squamous type who are not suitable for surgery or certain chemotherapy-radiation treatments and have not yet received treatment aimed at controlling advanced disease
- People with locally advanced or widespread NSCLC of the non-squamous type where lab tests show a specific protein (PD-L1) on 50% or more of tumour cells, without certain genetic changes (EGFR or ALK mutations), and who are not suitable for surgery or certain chemotherapy-radiation treatments and have not yet received treatment aimed at controlling advanced disease
- People with NSCLC (either squamous or non-squamous type) who have already received a type of chemotherapy called platinum-based therapy — and, if their cancer has certain genetic changes (EGFR or ALK mutations), have also received targeted treatments for those mutations
- People with extensive-stage small cell lung cancer (SCLC) who have not yet received treatment aimed at controlling advanced disease
- People for whom the treating doctor has already decided to prescribe a Tislelizumab-based treatment before enrolling in this study
- People who have already started treatment and received 1 to 2 cycles are still eligible to be enrolled (confirm with trial site)
- People who were originally being treated with the goal of cure but had to switch to a different treatment approach before completing the planned course are not automatically excluded (confirm with trial site)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have not signed a consent form agreeing to take part in the study
- People who are under 18 years of age at the time of signing the consent form
- People who are not able to fully understand what taking part in the study would involve
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Raoul De Jonge, Dr., Universitätsklinikum St. Pölten - Lilienfeld, Österreich
Phone: +49 (0)69 7601 3297
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.